Linked Life Data

16546289

Source:http://linkedlifedata.com/resource/pubmed/id/16546289

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-6-8
pubmed:abstractText
The clinical importance of drug-eluting stents (DESs) has been demonstrated by their unparalleled success in preventing restenosis after stenting procedures. The magnitude of success is historic despite their short history. The current DESs deliver a single drug aiming to prevent or minimize proliferation of smooth muscle cells. Since the restenosis process involves several different biological responses, the ability to deliver the right drugs at the right times is critical for further development of the second generation of DESs. As the type of drugs that can be delivered from DESs varies, it is imperative to understand the drug delivery mechanisms and the approaches available for drug coating on the stents. The drug delivery mechanisms of current DESs that have been used clinically and under clinical trials are explained.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0169-409X
pubmed:author
pubmed:issnType
Print
pubmed:day
3
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
387-401
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Mechanisms of controlled drug release from drug-eluting stents.
pubmed:affiliation
Akina Inc., 1291 Cumberland Ave., West Lafayette, IN 47906, USA.
pubmed:publicationType
Journal Article, Review